Novozymes North America, Inc.
Location
North Carolina
Founded
1969-02-28
Website
Risk Signals
989 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Industrial Organic Chemicals, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Novozymes North America, Inc.
Live alerts from global media, monitored by Business Radar
2025-02-26 (bt.dk)
Novonesis had a turnover of more than 29 billion kroner in 2024 | BT Business -
By 2024, Novonesis had a profit of DKK 2,063 billion, the company's annual accounts show.
Read more
2025-01-27 (pando.life)
Acusanji hydrolyzed enzyme market growth, prediction 2025 2032 << Pando >>
Posted by Cosperitaltomul. The “Acusan -en -hydraulic decomposition enzyme market” prioritizes coast management and improvement of efficiency. In addition, the report is both the market demand and the supply aspects. The Aikusan Ji -hydrolyzed enzyme market is expected to grow from 2025 to 15% at an annual rate of 2032. The entire reoperation is 198 pages. Acusanji hydrolysis ...
Read more
2024-11-07 (proinvestor.com)
Novonesis surprises with clarification in strong third quarter
Novonesis more or less came out of the third quarter of 2024 than expected. However, the joker was a clarification of the expectations for the whole year. This appears from the trading update from the group, which consists of the old Chr. Hansen and Novozymes after a successful merger. The enzyme and ingredient group
Read more
2024-08-27 (finans.dk)
Novonesis delivers double-digit growth in the second quarter and raises expectations
Novonesis raises expectations after strong organic growth calculated pro forma in the second quarter. Earnings are also better than expected.
Read more
2024-05-14 (pharmiweb.com)
Enzymes Market Forecasted to Grow at a CAGR of 6.6%, Reaching USD 21.3 Billion by 2032
The global enzymes market is projected to experience significant growth over the next decade, with its value expected to rise from USD 11.5 billion in 2022 to USD 21.3 billion by 2032, reflecting a compound annual growth rate (CAGR) of 6.6%. Several factors are driving this expansion.
Read more
2024-05-13 (biomassmagazine.com)
Novozymes: Bioenergy sales flat in Q2
Novozymes released second quarter 2019 financial results Aug. 8 reporting sales for its bioenergy segment were flat organically for the three months period and down 4 percent organically for the first half of the year.
Read more
2024-05-03 (vafo.dk)
Novonesis maintains its expectations after giant merger
Organic growth in Novonesis is four percent in the first quarter. In 2024, growth of five to seven percent is expected.
Read more
2024-04-30 (wallstreet-online.de)
Resolutions from the annual shareholders’ meeting 2024
30.04.2024 - Today an ordinary shareholders’ meeting was conducted. The following resolutions were made:• Approval of the audited Annual Report for 2023• Approval of distribution of profit with payment of an ordinary dividend of DKK 2.00 or EUR 0.27 per A/B ...
Read more
2024-02-09 (fodevarewatch.dk)
Labor law: Novozymes does not underpay female laboratory workers
HK Privat believed that the female laboratory technicians perform work of the same value as the male technicians.
Read more